<< Вернуться к списку статей журнала

Том 6 №4 2004 год - Нефрология и диализ

Выживаемость и факторы риска неблагоприятных исходов у больных на программном гемодиализе (Обзор литературы)

Бикбов Б.Т.

Аннотация: В настоящее время на заместительной почечной терапии в мире находятся почти полтора миллиона пациентов [110], и большая их часть (68,7%) - на программном гемодиализе. Количество больных, получающих лечение всеми видами ЗПТ, и в первую очередь гемодиализом, постоянно увеличивается, в среднем на 7% в год. Рост числа пациентов, получающих лечение ПГД, отмечается также и в Российской Федерации, причем темпы увеличения превышают среднемировые показатели [2]. Так по сравнению с предыдущим годом прирост количества больных на ПГД в Российской Федерации составил в 1999 г. 5,2%, в 2000 г. - 8,4% и в 2001 г. - 16,5%.

Для цитирования: Бикбов Б.Т. Выживаемость и факторы риска неблагоприятных исходов у больных на программном гемодиализе (Обзор литературы). Нефрология и диализ. 2004. 6(4):280-296. doi:

Весь текст

Ключевые слова: гемодиализ, выживаемость, факторы риска

Список литературы:

1. Андрусев А.М., Титова Н.Л., Бикбов Б.Т. и соавт. Перитонеальный диализ: ранние предикторы отдаленных результатов. Нефрология и диализ 2003; 5; 4: 362-368.
2. Бикбов Б.Т., Томилина Н.А. О состоянии заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 2001 г. Нефрология и диализ 2004; 6; 1: 4-42.
3. Волков М.М. Факторы течения заболевания, влияющие на выживаемость больных на хроническом гемодиализе. Нефрология 1997; 1: 43-49.
4. Климов А.Н., Никульчева Н.Г. Липиды, липопротеиды и атеросклероз. СПб.: Питер, 1995: 304.
5. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрология и диализ 2002; 4; 2: 113-117.
6. Назаров П.Г. Реактанты острой фазы воспаления. СПб.: Наука, 2001: 423.
7. Перекокин Ю.Н., Шило В.Ю., Гендлин Г.Е. и соавт. Скорость пульсовой волны и податливость аорты у больных на программном гемодиализе: связь с факторами риска, кальцинозом сердца и показателями внутрисердечной гемодинамики. Нефрология и диализ 2004; 6; 1: 62-69.
8. Потехин Н.П. Висцеральная патология у больных с терминальной почечной недостаточностью, получающих лечение программным гемодиализом: Автореф.. д-ра мед. наук. М.: 2000: 43.
9. Райхельсон К.Л. Влияние нутриционного статуса и гастродуоденальной патологии на прогноз и течение терминальной стадии хронической почечной недостаточности при применении активных методов лечения (гемодиализ, перитонеальный диализ, трансплантация): Автореф.. канд. мед. наук. СПб.: 1999: 24.
10. Amann K., Ritz C., Adamczak M. et al. Why is coronary heart disease of uremic patients so frequent and so devastating. Nephrol Dial Transplant 2003; 18: 631-640.
11. Apple F.S., Murakami M.M., Pearce L.A. et al. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation 2002; 106: 2941-2945.
12. Avram M.M., Mittman N., Myint M.M. et al. Importance of low serum intact parathyroid hormone as a predictor of mortality in hemodialysis and peritoneal dialysis patients: 14 years of prospective observation. Am J Kidney Dis 2001; 38: 1351-1357.
13. Bayes B., Pastor M.C., Bonal J. et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-112.
14. Beddhu S., Bruns F.J., Saul M. et al. A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609-613.
15. Benedetto F.A., Mallamaci F., Tripepi G. et al. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients. J Am Soc Nephrol 2001; 12: 2458-2464.
16. Bergstrom J., Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis 1998; 32: 834-841.
17. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and Epoetin. N Eng J Med 1998; 339: 584-590.
18. Blacher J., Guerin A.P., Pannier B. et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938.
19. Blacher J., Guerin A.P., Pannier B. et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99: 2434-2439.
20. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
21. Boaz M., Matas Z., Biro A. et al. Comparison of hemostatic factors and serum malondialdehyde as predictive factors for cardiovascular disease in hemodialysis patients. Am J Kidney Dis 1999; 34: 438-444.
22. Bologa R.M., Levine D.M., Parker T.S. et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
23. Bryant D., Becker L., Richardson J. et al. Cardiac failure in transgenic mice with myocardial expression of TNFα. Circulation 1998; 97: 1375-1381.
24. Burke A.P., Tracy R.P., Kolodgie F. et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death. Circulation 2002; 105: 2019-2023.
25. Cano N.J.M., Roth H., Aparicio M. et al. Malnutrition in hemodialysis diabetic patients: evaluation and prognostic influence. Kidney Int 2002; 62: 593-601.
26. Charlson M.E., Pompei P., Ales K.L. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 373-383.
27. Charra B., Calemard E., Chazot C. et al. Survival as an index of adequacy of dialysis. Kidney Int 1992; 41: 1286-1291.
28. Chertow G.M., Owen W.F., Lazarus J.M. et al. Exploring the reverse J-shaped curve between urea reduction ratio and mortality. Kidney Int 1999; 56: 1872-1878.
29. Cheung A.K., Sarnak M.J., Yan G. et al. Atherosclerotic cardiovascular disease risks in chronic haemodialysis patients. Kidney Int 2000; 58: 353-362.
30. Collins A.J., Li S., Peter W.S. et al. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 2001; 12: 2465-2473.
31. Collins A.J., Hao W., Xia H. et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-1074.
32. Davies S.J., Phillips L., Naish P.F. et al. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092.
33. De Lima J.J.G., Vieira M.L.C., Abensur H. et al. Baseline blood pressure and other variables influencing survival on haemodialysis of patients without overt cardiovascular disease. Nephrol Dial Transplant 2001; 16: 793-797.
34. Descamps-Latscha B., Witko-Sarsat V. Importance of oxidatively modified proteins in chronic renal failure. Kidney Int 2001; 59 [Suppl 78]: S108-S113.
35. Dhingra R.K., Young E.W., Hulbert-Shearon T.E. et al. Type of vascular access and mortality in U.S. hemodialysis patients. Kidney Int 2001; 60: 1443-1451.
36. Di Iorio B.R., Bellizzi V., Cillo N. et al. Vascular access for hemodialysis: the impact on morbidity and mortality. J Nephrol 2004; 17: 19-25.
37. Dierkes J., Domrose U., Westphal S. et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation 2000; 102: 1964-1969.
38. Disney A.P.S., Russ Graeme R. Australia and New Zealand Dialysis and Transplant Registry Report 2001. Adelaide: ANZDATA, 2001: 105.
39. Eknoyan G., Beck G.J., Cheung A.K. et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Eng J Med 2002; 347: 2010-2019.
40. ERA-EDTA Registry: ERA-EDTA Registry 2001 Annual Report. Academic Medical Center. Amsterdam, Netherlands: 2003: 81.
41. Foley R.N., Parfrey P.S., Hamett J.D. et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192.
42. Foley R.N., Herzog C.A., Collins A.J. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790.
43. Foley R.N., Parfrey P.S., Kent G.M. et al. Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol 2000; 11: 912-916.
44. Fong I.W. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis. CMAJ 2000; 163: 49-56.
45. Fukuta H., Hayano J., Ishihara S. et al. Prognostic value of heart rate variability in patients with end-stage renal disease on chronic haemodialysis. Nephrol Dial Transplant 2003; 18: 318-325.
46. Ganesh S.K., Hulbert-Shearon T., Port F.K. et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol 2003; 14: 415-424.
47. Ganesh S.K., Stack A.G., Levin N.W. et al. Association of elevated serum PO4, Ca x PO4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138.
48. Garfray A., Patel K., Whitaker P. et al. Albumin as an outcome measure in hemodialysis patients: the effect of variation in assay method. Nephrol Dial Transplant 2000; 15: 1819-1822.
49. Gerdemann A., Wagner Z., Solf A. et al. Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: potential importance of dialysate quality. Nephrol Dial Transplant 2002; 17: 1045-1049.
50. Girndt M., Sester M., Sester U. et al. Molecular aspects of T- and
51. B-cell function in uremia. Kidney Int 2001; 59 [Suppl 78]: 206-211.
52. Goodkin D.A., Bragg-Gresham J.L., Koenig K.G. et al. Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 2003; 14: 3270-3277.
53. Guarnieri G., Antonione R., Biolo G. Mechanisms of malnutrition in uremia. J Ren Nutr 2003; 13: 153-157.
54. Hathaway D.K., Cashion A.K., Milstead E.J. et al. Autonomic dysregulation in patients awaiting kidney transplantation. Am J Kidney Dis 1998; 32: 221-229.
55. Hayano J., Takahashi H., Toriyama T. et al. Prognostic value of heart rate variability during long-term follow-up in chronic haemodialysis patients with end-stage renal disease. Nephrol Dial Transplant 1999; 14: 1480-1488.
56. Hemmelgarn B.R., Manns B.J., Quan H. et al. Adapting the Charlson Comorbidity Index for use in patients with ESRD. Am J Kidney Dis 2003; 42: 125-132.
57. Himmelfarb J., Stenvinkel P., Ikizler T.A. et al. The elephant in uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
58. Hocher B., Ziebig R., Altermann C. et al. Different impact of biomarkers as mortality predictors among diabetic and nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003; 14: 2329-2337.
59. Hurst R.T., Lee R.W. Increased incidence of coronary atherosclerosis in type 2 diabetes mellitus: mechanisms and management. Ann Intern Med 2003; 139: 824-834.
60. Innes A., Charra B., Burden R.P. et al. The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 1999; 14: 919-922.
61. Iseki K., Miyasato F., Tokuyama K. et al. Low diastolic blood pressure, hypoalbuminemia, and risk of death in a cohort of chronic hemodialysis patients. Kidney Int 1997; 51: 1212-1217.
62. Iseki K., Tozawa M., Takishita S. Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients. Nephrol Dial Transplant 2003; 18: 782-787.
63. Iseki K., Yamazato M., Tozawa M. et al. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int 2002; 61: 1887-1893.
64. Izuhara Y., Miyata T., Saito K. et al. Ultrapure dialysate decreases plasma pentosidine, a marker of «carbonyl stress». Am J Kidney Dis 2004; 43: 1024-1029.
65. Jaar B.G., Hermann J.A., Furth S.L. et al. Septicemia in diabetic hemodialysis patients: comparison of incidence, risk factors, and mortality with nondiabetic hemodialysis patients. Am J Kidney Dis 2000; 35: 282-292.
66. Jaber B.L., Cendoroglo M., Balakrishnan V.S. et al. Apoptosis of leukocytes: basic concepts and implications in uremia. Kidney Int 2001; 59 [Suppl 78]: 197-205.
67. Johnson J.G., Gore S.M., Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant 1999; 14: 2156-2164.
68. Jungers P. Late referral: loss of chance for the patient, loss of money for society. Nephrol Dial Transplant 2002; 17: 371-375.
69. Kaizu Y., Kimura M., Yoneyama T. et al. Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am J Kidney Dis 1998; 31: 93-100.
70. Kalantar-Zadeh K., Block G., Humphreys M.H. et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
71. Kalantar-Zadeh K., Kopple J.D., Block G. et al. Association among SF36 quality of life measures and nutrition, hospitalization, and mortality in hemodialysis. J Am Soc Nephrol 2001; 12: 2797-2806.
72. Kalantar-Zadeh K., Kopple J.D., Humphreys M.H. et al. Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1507-1519.
73. Kaysen G.A., Chertow G.M., Adhikarla R. et al. Inflammation and dietary protein intake exert competing effects on serum albumin and creatinine in hemodialysis patients. Kidney Int 2001; 60: 333-340.
74. Kaysen G.A. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 2001; 12: 1549-1557.
75. Kazmi W.H., Obrador G.T., Khan S.S. et al. Late nephrology referral and mortality among end-stage renal disease: a propensity score analysis. Nephrol Dial Transplant 2004; 19: 1808-1814.
76. Khan I.H., Campbell M.K., Cantarovich D. et al. Comparing outcomes in renal replacement therapy: how should we correct for case mix? Am J Kidney Dis 1998; 31: 471-478.
77. Kimmel P.L., Peterson R.A., Weihs K.L. et al. Multiple measurements of depression predict mortality in a longitudinal study of chronic hemodialysis outpatients. Kidney Int 2000; 57: 2093-2098.
78. Kimmel P.L., Varela M.P., Peterson R.A. et al. Interdialytic weight gain and survival in hemodialysis patients: effects of duration of ESRD and diabetes mellitus. Kidney Int 2000; 57: 1141-1151.
79. Kimmel P.L., Chawla L.S., Amarasinghe A. et al. Anthropometric measures, cytokines and survival in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 326-332.
80. Kimoto E., Shoji T., Emoto M. et al. Effect of diabetes on uremic dyslipidemia. J Atheroscler Thromb 2002; 9: 305-313.
81. Kleophas W., Haastert B., Backus G. et al. Long-term experience with an ultrapure individual dialysis fluid with a batch type machine. Nephrol Dial Transplant 1998; 13: 3118-3125.
82. Koch M., Kutkuhn B., Grabensee B. et al. Apolipoprotein A, fibrinogen, age, and history of stroke are predictors of death in dialysed diabetic patients: a prospective study in 412 subjects. Nephrol Dial Transplant 1997; 12: 2603-2611.
83. Koda Y., Nishi S., Suzuki M. et al. Lipoprotein(a) is a predictor for cardiovascular mortality of hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S251-S253.
84. Kopple J.D. McCollum award lecture, 1996: Protein-energy malnutrition in maintenance dialysis patients. Am J Clin Nutr 1997; 65: 1544-1557.
85. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part I: Aging Arteries: a «set up» for vascular disease. Circulation 2003; 107: 139-146.
86. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises. Part II: The aging heart in health: links to heart disease. Circulation 2003; 107: 346-354.
87. Laurent G., Charra B. The results of an 8 h thrice weekly haemodialysis schedule. Nephrol Dial Transplant 1998; 13 [Suppl 6]: 125-131.
88. Levey A., Beto J.A., Coronado B.E. et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906.
89. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
90. Locatelli F., Canaud B., Eckardt K.-U. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280.
91. Locatelli F., Covic A., Chazot C. et al. Hypertension and cardiovascular risk assessment in dialysis patients. Nephrol Dial Transplant 2004; 19: 1058-1068.
92. London G.M., Guerin A.P., Marchais S.J. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740.
93. London G.M., Marchais S.J., Guerin A.P. et al. Arterial structure and function in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 1713-1724.
94. London G.M., Pannier B., Agharazii M. et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 2004; 65: 700-704.
95. London G.M., Pannier B., Guerin A.P. et al. Alterations of left ventricular hypertrophy and survival of patients receiving hemodialysis: follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767.
96. Longenecker J.C., Klag M.J., Marcovina S.M. et al. Small apolipoprotein(a) size predicts mortality in end-stage renal disease: The CHOICE study. Circulation 2002; 106: 2812-2818.
97. Lowrie E.G., Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
98. Maisonneuve P., Agodoa L., Gellert R. et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99.
99. Malaponte G., Bevelacqua V., Fatuzzo P. et al. IL-1β, TNF-α and IL-6 release from monocytes in hemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 2002; 17: 1964-1970.
100. Mapes D.L., Lopes A.A., Satayathum S. et al. Health-related quality of life as a predictor of mortality and hospitalization: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Kidney Int 2003; 64: 339-349.
101. Marcen R., Teruel J.L., de la Cal M.A. et al. The impact of malnutrition in morbidity and mortality in stable haemodialysis patients. Nephrol Dial Transplant 1997; 12: 2324-2331.
102. Massry S.G., Smogorzewski M. Dysfunction of polymorphonuclear leukocytes in uremia: Role of parathyroid hormone. Kidney Int 2001; 59 [Suppl 78]: S195-S196.
103. Mazzuchi N., Carbonell E., Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int 2000; 58: 2147-2154.
104. Merkus M.P., Jager K.J., Dekker F.W. et al. Predictors of poor outcome in chronic dialysis patients: the Nederlands cooperative study on the adequacy of dialysis. Am J Kidney Dis 2000; 35: 69-79.
105. Metcalfe W., Khan I.H., Prescott G.J. et al. Can we improve early mortality in patients receiving renal replacement therapy. Kidney Int 2000; 57: 2539-2545.
106. Meur Y.L., Lorgeot V., Aldigier J.-C. et al. Whole blood production of monocytic cytokines (IL-1β, IL-6, TNF-α, sIL-6R, IL-1R) in haemodialysed patients. Nephrol Dial Transplant 1999; 14: 2420-2426.
107. Minamoto T., Mai M., Ronai Z.E. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis 1999; 20: 519-527.
108. Minino A.M., Arias E., Kochanek K.D. et al. Deaths: final data for 2000. National Vital Statistics Reports 2002; 50: 1-120.
109. Miskulin D.C., Athienites N.V., Yan G. et al. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int 2001; 60: 1498-1510.
110. Miyata T., Sugiyama S., Saito A. et al. Reactive carbonyl compounds related uremic toxicity («carbonyl stress»). Kidney Int 2001; 59 [Suppl 78]: S25-S31.
111. Moeller S., Gioberge S., Brown G. ESRD patients in 2001: global overview of patients, treatment modalities and developing trends. Nephrol Dial Transplant 2002; 17: 2071-2076.
112. Morioka T., Emoto M., Tabata T. et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 909-913.
113. Moustapha A., Naso A., Nahlawi M. et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141.
114. Nassar G.M., Ayus J.C. Infectious complications of the hemodialysis access. Kidney Int 2001; 60: 1-13.
115. Nishizawa Y., Shoji T., Kakiya R. et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int 2003; 63 [Suppl 84]: S117-S120.
116. Nishizawa Y., Shoji T., Maekawa K. et al. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2003; 41 [Suppl 1]: S76-S79.
117. Obrador G.T., Arora P., Kausz A.T. et al. Level of renal function at the initiation of dialysis in the U.S. end-stage renal disease population. Kidney Int 1999; 56: 2227-2235.
118. Ohashi H., Oda H., Ohno M. et al. Lipoprotein(a) as a risk factor for coronary artery disease in hemodialysis patients. Kidney Int 1999; 56 [Suppl 71]: S242-S244.
119. Owen W.F., Lew N.L., Liu Y. et al. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Eng J Med 1993; 329: 1001-1006.
120. Owen W.F., Lowrie E.G. C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627-636.
121. Panici V., Maggiore U., Taccola D. et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154-1160.
122. Panuccio V., Tripepi R., Tripepi G. et al. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004; 43: 479-484.
123. Paoletti E., Specchia C., Di Maio G. et al. The worsening of left ventricular hypertrophy is the strongest predictor of sudden cardiac death in haemodialysis patients: a 10 year survey. Nephrol Dial Transplant 2004; 19: 1829-1834.
124. Parfrey P.S., Foley R.N. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615.
125. Parfrey P.S., Foley R.N., Harnett J.D. et al. Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol Dial Transplant 1996; 11: 1277-1285.
126. Park C.W., Shin Y.S., Kim C.M. et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002; 40: 1230-1239.
127. Pastan S., Soucie J.M., McClellan W.M. Vascular access and increased risk of death among hemodialysis patients. Kidney Int 2002; 62: 620-626.
128. Perna A.F., Ingrosso D., Lombardi C. et al. Possible mechanisms of homocysteine toxicity. Kidney Int 2003; 63 [Suppl 84]: 137-140.
129. Pertosa G., Grandaliano G., Gesualdo L. et al. Clinical relevance of cytokine production in hemodialysis. Kidney Int 2000; 58 [Suppl 76]: S104-S111.
130. Pifer T.B., McCullough K.P., Port F.K. et al. Mortality risk in hemodialysis patients and changes in nutritional indicators: DOPPS. Kidney Int 2002; 62: 2238-2245.
131. Port F.K., Ashby V.B., Dhingra R.K. et al. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients. J Am Soc Nephrol 2002; 13: 1061-1066.
132. Port F.K., Hulbert-Shearon T.E., Wolfe R.A. et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 1999; 33: 507-517.
133. Powe N.R., Jaar B., Furth S.L. et al. Septicemia in dialysis patients: Incidence, risk factors, and prognosis. Kidney Int 1999; 55: 1081-1090.
134. Qureshi A.R., Alvestrand A., Divino-Filho J.C. et al. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002; 13: S28-S36.
135. Rahman M., Fu P., Sehgal A.R. et al. Interdialytic weight gain, compliance with dialysis regimen, and age are independent predictors of blood pressure in hemodialysis patients. Nephrol Dial Transplant 2000; 35: 257-265.
136. Raj D.S.C., Charra B., Pierratos A. et al. In search of ideal hemodialysis: is prolonged frequent dialysis the answer? Am J Kidney Dis 1999; 34: 597-310.
137. Reddan D.N., Klassen P.S. , Szczech L.A. et al. White blood cells as a novel mortality predictor in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 1167-1173.
138. Ronco C., Fabris A., Feriani M. Hemodialysis fluid composition. In: Replacement of renal function by dialysis. Ed. Jacobs C. et al. Dordrecht: Kluwer, 1996: 256-276.
139. Ross R. Atherosclerosis - an inflammatory disease. N Eng J Med 1999; 340: 115-126.
140. Salomaa V., Riley W., Kark J.D. et al. Non-insulin-dependent diabetes mellitus and fasting glucose and insulin concentrations are associated with arterial stiffness indexes. Circulation 1995; 91: 1432-1443.
141. Santoro A., Mancini E. Cardiac effects of inflammation in dialysis patients. Nephrol Dial Transplant 2002; 17 [Suppl 8]: 10-15.
142. Schachinger V., Zeiher A.M. Atherogenesis - recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 2002; 17: 2055-2064.
143. Schiffl H., Lang S.M., Stratakis D. et al. Effects of ultrapure dialysis fluid on nutritional status and inflammatory parameters. Nephrol Dial Transplant 2001; 16: 1863-1869.
144. Schwedler S.B., Metzger T., Schinzel R. et al. Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002; 62: 301-310.
145. Scott B., Deman A., Peeters P. et al. Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 737-742.
146. Shinohara K., Shoji T., Emoto M. et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894-1900.
147. Shinzato T., Nakai S., Akiba T. et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy. Nephrol Dial Transplant 1997; 12: 884-888.
148. Shinzato T., Nakai S., Akiba T. et al. Report on the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996. Kidney Int 1999; 55: 700-712.
149. Shoji T., Emoto M., Shinohara K. et al. Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 2001; 12: 2117-2124.
150. Shoji T., Fukumoto M., Kimoto E. et al. Antibody to oxidized low-density lipoprotein and cardiovascular mortality in end-stage renal disease. Kidney Int 2002; 62: 2230-2237.
151. Smogorzewski M., Massry S.G. Defects in B-cell function and metabolism in uremia: role of parathyroid hormone. Kidney Int 2001; 59 [Suppl 78]: S186-S189.
152. Steinerova A., Racek J., Stozicky F. et al. Antibodies against oxidized LDL - theory and clinical use. Physiol Res 2001; 50: 131-141.
153. Stenvinkel P. Endothelial dysfunction and inflammation - is there a link? Nephrol Dial Transplant 2001; 16: 1968-1971.
154. Stenvinkel P., Wanner C., Metzger T. et al. Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791-1798.
155. Stevens L.A., Djurdjev O., Cardew S. et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779.
156. Stolear J.C., Georges B., Shita A. et al. The predictive value of cardiac troponin T measurements in subjects on regular hemodialysis. Nephrol Dial Transplant 1999; 14: 1961-1967.
157. Suliman M.E., Heimburger O., Barany P. et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614-1622.
158. Suliman M.E., Qureshi A.R., Barany P. et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000; 57: 1727-1735.
159. Szczech L.A., Reddan D.N. , Klassen P.S. et al. Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients. Nephrol Dial Transplant 2003; 18: 1585-1591.
160. Taal M.W., Roe S., Masud T. et al. Total hip bone mass predicts survival in chronic hemodialysis patients. Kidney Int 2003; 63: 1116-1120.
161. The UK Renal Registry Report 2002. Ed.: Ansell D., Feest, T. UK Renal Registry, Bristol, UK, 2001: 139.
162. Tozawa M., Iseki K., Iseki C. et al. Pulse pressure and risk of total mortality and cardiovascular events in patients on chronic hemodialysis. Kidney Int 2002; 61: 717-726.
163. U.S. Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2003: 560.
164. Umen A.J., Le C.T. Prognostic factors, models and related statistical problems in the survival of endstage renal disease patients on hemodialysis. Stat Med 1986; 5: 637-652.
165. van den Hoogen P.C.W., Fescens E.J.M., Nagelkerke N.J.D. et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Circulation 2000; 342: 1-8.
166. van Dijk P.C.W., Jager K.J., de Charro F. et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. Nephrol Dial Transplant 2001; 16: 1120-1129.
167. van Manen J.G., Korevaar J.C., Dekker F.W. et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; 40: 82-89.
168. Vanholder R., Cornelis R. , Dhondt A. et al. The role of trace elements in uraemic toxicity. Nephrol Dial Transplant 2002; 17 [Suppl 2]: 2-8.
169. Wanner C. Importance of hyperlipidaemia and therapy in renal patients. Nephrol Dial Transplant 2000; 15 [Suppl 5]: 92-96.
170. Wanner C., Metzger T. C-reactive protein a marker for all-cause and cardiovascular mortality in haemodialysis patients. Nephrol Dial Transplant 2002; 17 [Suppl 8]: 29-32.
171. Wu M.-S., Yu C.-C., Yang C.-W. et al. Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 1997; 12: 2105-2110.
172. Yeun J.Y., Levine R.A., Mantadilok V. et al. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35: 469-476.
173. Yokoyama T., Nakano M., Bednarczyk J.L. et al. TNF-α provokes a hypertrophic growth response in adult cardiac myocytes. Circulation 1997; 95: 1247-1252.
174. Zager P.G., Nicolic J., Brown R.H. et al. «U» curve association of blood pressure and mortality in hemodialysis patients. Kidney Int 1998; 54: 561-569.
175. Zoccali C., Mallamaci F., Tripepi G. et al. Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney Int 2003; 64: 579-584.
176. Zoccali C., Benedetto F.A., Maas R. et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
177. Zoccali C., Benedetto F.A., Mallamaci F. et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-2774.
178. Zoccali C., Bode-Boger S.M., Mallamaci F. et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.

Другие статьи по теме

• Субъективные показатели физического здоровья связанные с выживаемостью больных на гемодиализе
• Факторы риска смерти больных, впервые начинающих лечение гемодиализом (по данным Регистра Российского диализного общества)
• Динамика артериальной гипертензии и выживаемость у пациентов на гемодиализ
• Хорошо ли мы лечим дефицит железа при анемии ХБП у пациентов на гемодиализе? Связь между ферритином сыворотки и 1-годичной выживаемостью